Shuang Liu1,2, Ting Jiang1,2, Lin Xiao3, Shanfei Yang1,2, Qing Liu2,4, Yuanhong Gao1,2, Gong Chen5,2, Weiwei Xiao1,2. 1. Departments of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. 2. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. 3. Department of Oncology, Section II, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, People's Republic of China. 4. Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China. 5. Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
Abstract
BACKGROUND: Total neoadjuvant therapy (TNT) is a novel approach for locally advanced rectal cancer (LARC), which attempts to deliver both systemic chemotherapy and neoadjuvant chemoradiotherapy prior to surgery. However, its efficacy and safety remain controversial in randomized controlled trials (RCTs). We conducted this meta-analysis to assess such concerns. MATERIALS AND METHODS: Head-to-head phase II/III RCTs were searched in Embase, PubMed, Web of Science, and the Cochrane Library, as well as other sources. The primary endpoint was pathologic complete response (pCR). Secondary endpoints were disease-free survival (DFS), overall survival (OS), local recurrence-free survival, distant metastasis-free survival, and the R0 resection rate. RESULTS: Eight phase II/III RCTs involving 2,196 patients with LARC were assessed. The primary analysis demonstrated a statistically significant improvement in the pCR rate for TNT treatment (odds ratio, 1.77; 95% confidence interval [CI], 1.28-2.45; p = .0005). TNT treatment also showed improvements in DFS and OS outcomes compared with standard chemoradiotherapy (hazard ratio [HR], 0.83; 95% CI, 0.72-0.96; p = .03 and HR, 0.88; 95% CI, 0.74-1.05; p = .15). In addition, TNT treatment showed significant efficacy in reducing the risk of distant metastasis (HR, 0.81; 95% CI, 0.68-0.95; p = .012). CONCLUSION: The overall pCR rate may be improved with TNT compared with standard treatment. The TNT strategy may also improve DFS and OS and reduce the risk of distant metastasis. IMPLICATIONS FOR PRACTICE: Locally advanced rectal cancer (LARC) is a relatively common disease, with a poor prognosis because of its high metastatic potential. The role of total neoadjuvant therapy (TNT) has always been controversial. This meta-analysis found that TNT in LARC is associated with a significant improvement in overall pathologic complete response rate, disease-free survival, overall survival, and distant metastasis-free survival compared with standard treatment. TNT is a promising strategy for LARC, especially for patients who have little desire for surgery.
BACKGROUND: Total neoadjuvant therapy (TNT) is a novel approach for locally advanced rectal cancer (LARC), which attempts to deliver both systemic chemotherapy and neoadjuvant chemoradiotherapy prior to surgery. However, its efficacy and safety remain controversial in randomized controlled trials (RCTs). We conducted this meta-analysis to assess such concerns. MATERIALS AND METHODS: Head-to-head phase II/III RCTs were searched in Embase, PubMed, Web of Science, and the Cochrane Library, as well as other sources. The primary endpoint was pathologic complete response (pCR). Secondary endpoints were disease-free survival (DFS), overall survival (OS), local recurrence-free survival, distant metastasis-free survival, and the R0 resection rate. RESULTS: Eight phase II/III RCTs involving 2,196 patients with LARC were assessed. The primary analysis demonstrated a statistically significant improvement in the pCR rate for TNT treatment (odds ratio, 1.77; 95% confidence interval [CI], 1.28-2.45; p = .0005). TNT treatment also showed improvements in DFS and OS outcomes compared with standard chemoradiotherapy (hazard ratio [HR], 0.83; 95% CI, 0.72-0.96; p = .03 and HR, 0.88; 95% CI, 0.74-1.05; p = .15). In addition, TNT treatment showed significant efficacy in reducing the risk of distant metastasis (HR, 0.81; 95% CI, 0.68-0.95; p = .012). CONCLUSION: The overall pCR rate may be improved with TNT compared with standard treatment. The TNT strategy may also improve DFS and OS and reduce the risk of distant metastasis. IMPLICATIONS FOR PRACTICE: Locally advanced rectal cancer (LARC) is a relatively common disease, with a poor prognosis because of its high metastatic potential. The role of total neoadjuvant therapy (TNT) has always been controversial. This meta-analysis found that TNT in LARC is associated with a significant improvement in overall pathologic complete response rate, disease-free survival, overall survival, and distant metastasis-free survival compared with standard treatment. TNT is a promising strategy for LARC, especially for patients who have little desire for surgery.
Authors: Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila Journal: Lancet Oncol Date: 2015-07-14 Impact factor: 41.316
Authors: Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2017-03-01 Impact factor: 508.702
Authors: Zhifei Sun; Mohamed A Adam; Jina Kim; Mithun Shenoi; John Migaly; Christopher R Mantyh Journal: J Am Coll Surg Date: 2016-01-20 Impact factor: 6.113
Authors: Maxime J M van der Valk; Corrie A M Marijnen; Boudewijn van Etten; Esmée A Dijkstra; Denise E Hilling; Elma Meershoek-Klein Kranenbarg; Hein Putter; Annet G H Roodvoets; Renu R Bahadoer; Tone Fokstuen; Albert Jan Ten Tije; Jaume Capdevila; Mathijs P Hendriks; Ibrahim Edhemovic; Andrès M R Cervantes; Derk Jan A de Groot; Per J Nilsson; Bengt Glimelius; Cornelis J H van de Velde; Geke A P Hospers Journal: Radiother Oncol Date: 2020-03-30 Impact factor: 6.280
Authors: Leonardo C Duraes; Scott R Steele; Michael A Valente; Olga A Lavryk; Tara M Connelly; Hermann Kessler Journal: Int J Colorectal Dis Date: 2022-03-21 Impact factor: 2.571
Authors: Farshid Dayyani; Brian R Smith; Ninh T Nguyen; Shaun Daly; Marcelo W Hinojosa; Steven N Seyedin; Jeffrey Kuo; Jason B Samarasena; John G Lee; Thomas H Taylor; May T Cho; Maheswari Senthil Journal: Future Oncol Date: 2022-05-23 Impact factor: 3.674
Authors: Andrea M Guida; Bruno Sensi; Vincenzo Formica; Rolando M D'Angelillo; Mario Roselli; Giovanna Del Vecchio Blanco; Piero Rossi; Gabriella T Capolupo; Marco Caricato; Giuseppe S Sica Journal: Biol Direct Date: 2022-06-13 Impact factor: 7.173
Authors: Marloes Swets; Cristina Graham Martinez; Shannon van Vliet; Arjan van Tilburg; Hans Gelderblom; Corrie A M Marijnen; Cornelis J H van de Velde; Iris D Nagtegaal Journal: Histopathology Date: 2022-07-14 Impact factor: 7.778